文献リスト

1）Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363: 733-42

2）Roodman GD. Mechanism of bone metastasis. N Engl J Med. 2004; 350: 1655-64

3）Al Husaini H, Wheatley-Price P, Clemons M, et al. Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol. 2009; 4: 251-9

4）Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80: 1588-94

5）Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retro­spective study. Lung Cancer. 2007; 57: 229-32

6）Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21: 3150-7

7）Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100: 2613-21

8）Henry DH, Costa L, Goldwasser F, et al. Rando­mized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metasta­ses in patients with advanced cancer （excluding breast and prostate cancer） or multiple myeloma. J Clin Oncol. 2011; 29: 1125-32

9）Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377: 813-22

10）Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28: 5132-9

11）Yoneda T, Hagino H, Sugimoto T, et al. Bisphos­phonate-related osteone­crosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society,Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radi­ology, and Japanese Society of Oral and Maxillo­facial Surgeons. J Bone Miner Metab. 2010; 28: 365-83

12）Xie J, Namjoshi M, Wu EQ, et al. Economic eva­luation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm. 2011; 17: 621-43

13）Stopeck A, Rader M, Henry D, et al. Cost-effecti­veness of denosumab vs zoledronic acid for pre­vention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Exon. 2012: 15: 712-23

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp